此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

复发性髓母细胞瘤和原始神经外胚层肿瘤的疫苗免疫治疗 (Re-MATCH)

2026年7月23日 更新者:University of Florida

清髓性化疗和造血干细胞移植恢复期间复发性髓母细胞瘤和原始神经外胚层肿瘤过继性 T 细胞治疗

免疫疗法是一种治疗癌症的特殊方法,已在成年患者中显示出治疗黑色素瘤、恶性脑肿瘤和其他癌症的希望。 研究人员将利用他们从这些研究中获得的经验来尝试改善受复发性脑肿瘤影响的儿童的预后。

大约 35 名首次复发的髓母细胞瘤 (reMB)/幕上原始神经外胚层肿瘤 (PNETs) 患者将接受肿瘤特异性免疫细胞和树突状细胞疫苗的治疗,以了解它们对肿瘤的影响。

研究概览

详细说明

恶性脑肿瘤现在是儿童癌症死亡的最常见原因。 尽管采取了包括手术、颅脑放疗和大剂量化疗以及外周血干细胞移植在内的侵略性和高毒性的多模式治疗,但几乎一半的儿童被诊断出患有最常见的恶性脑肿瘤、髓母细胞瘤 (MB) 和原始神经外胚层肿瘤( PNET),仍将死于复发性疾病。 此外,幸存者往往会留下严重的和终生与治疗相关的认知和运动缺陷。 开发更有效的肿瘤特异性疗法,不会增加现有疗法的进一步毒性,对于改善受 MB/PNETs 影响的儿童的临床结果至关重要。 针对脑肿瘤内表达的肿瘤特异性抗原的免疫疗法是一种可能满足这一明确而紧迫需求的方式。

尽管在针对成人恶性脑肿瘤的免疫治疗试验中观察到了相当大的进步和有希望的临床结果,但儿童脑肿瘤免疫治疗的努力仅限于相对较少的著名研究。 这至少部分是由于可用于基于肿瘤细胞的疫苗制剂的活肿瘤组织通常有限,以及缺乏在这些癌症中持续表达的肿瘤特异性抗原的鉴定。

使用负载总肿瘤 RNA (TTRNA) 的树突状细胞 (DC) 是杜克大学的先驱,作为一种新平台,可诱导针对恶性肿瘤细胞内存在的各种未表征和患者特异性抗原的有效免疫反应。 Duke 证明,可以使用现有的分子技术从少至 500 个分离的儿科和成人脑肿瘤细胞中高保真地扩增足够的 RNA 用于临床疫苗制备,从而允许从手术活检甚至显微解剖的档案肿瘤标本中制备疫苗。

在化疗恢复期间进行的免疫疗法可能具有巨大的优势,因为淋巴细胞清除预处理方案后的过继细胞疗法已成为晚期和难治性黑色素瘤的最有效治疗策略。 我们的假设是,在清髓性化疗恢复期间针对复发性 MB/PNET 的 DC + 离体扩增自体淋巴细胞转移 (xALT) 疗法是安全的,并将延长患有复发性 MB/PNET 的儿童和年轻人的生存期。

在这项研究中,研究人员将使用自体肿瘤特异性 T 细胞免疫疗法 (TTRNA-xALT) 和载有 TTRNA 的树突状细胞疫苗治疗完成根治性放射治疗后首次复发的 reMB/PNETs 患者。

在手术切除、活检或细胞学检查并确认病理诊断后,患者将根据 HDC 的资格被纳入 A 组(高剂量化疗或 HDC)或 B 组(非清髓性或 NMA 挽救性化疗)。 局部复发且之前 HDC+ 外周血干细胞移植 (PBSCT) 未失败的患者将被纳入 A 组。患有播散性疾病、之前 HDC+PBSCT 失败或根据整体健康状况被认为不适合 HDC 的患者, 但在其他方面符合资格标准,将被纳入 B 组。所有患者都将接受 DC + xALT 治疗。

研究类型

介入性

注册 (实际的)

26

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Los Angeles、California、美国、90027
        • Children's Hospital Los Angeles
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • Children's National Medical Center
    • Florida
      • Gainesville、Florida、美国、32610
        • University of Florida

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 30年 (孩子、成人)

接受健康志愿者

不

描述

纳入标准:

筛选:

  • 年龄≤30岁。
  • 自确定性局灶性 +/- 颅脊髓照射完成后疑似 MB/PNET 首次复发/进展。 如果患者在接受确定性局灶性 +/- 颅脊髓照射之前出现疾病进展,但随后确定性放疗失败并且在入组时首次复发/进展,则不会取消患者的入组资格。 由于遗传疾病而无法接受放射治疗的患者,这些疾病使他们处于辐射诱发的继发性恶性肿瘤(即 Gorlin 综合征或 NF1 突变)有资格在第一次疾病复发/进展时入组。

重新匹配协议:

  • 患者必须有经组织学证实的复发性 MB/PNET,即在完成根治性放疗 +/- 颅脊髓照射后首次复发/进展。 首次复发/进展的患者由于遗传疾病而无法接受放射治疗,这使他们处于辐射诱发的继发性恶性肿瘤(即 Gorlin 综合征或 NF1 突变)有资格入组。
  • 有神经功能缺陷的患者在注册前应至少稳定 1 周。
  • Karnofsky 表现状态≥ 50% 或 Lansky 表现得分 ≥ 50。
  • 中性粒细胞绝对计数 (ANC) ≥ 1000/µl(不受支持)。
  • 血小板 ≥ 100,000/µl(无支持)。
  • 血红蛋白 > 8 g/dL(可能支持)。
  • 血清肌酐≤机构正常值上限
  • 胆红素≤年龄正常上限的1.5倍。
  • 血清谷氨酸草酰乙酸转氨酶 (ALT) ≤ 3 倍机构年龄正常上限。
  • 血清谷氨酸草酰乙酸转氨酶 (AST) ≤ 3 倍机构年龄正常上限。
  • 在本研究中接受治疗时,有生育或生育潜力的患者必须愿意使用医学上可接受的节育形式,包括禁欲。
  • 如果 PBSC 或骨髓(CD34 计数至少 2x10^6/kg)之前未储存且可供使用,则患者或患者监护人同意在注册后采集外周血干细胞 (PBSC) 和/或骨髓。
  • 根据机构指南签署的知情同意书必须在注册前获得。

排除标准:

  • 在研究期间怀孕或需要母乳喂养。
  • 需要治疗的活动性感染或不明原因的发热 (> 101.5F) 疾病。
  • 已知的免疫抑制性疾病、人类免疫缺陷病毒感染或乙型或丙型肝炎病毒携带者。
  • 患有活动性肾脏、心脏(充血性心力衰竭、心肌梗塞、心肌炎)或肺部疾病的患者。
  • 因身体状况而同时接受免疫抑制剂治疗的患者。
  • 需要根治性放疗治疗复发性 MB/PNET 的患者。 如果需要局部控制,可以在免疫治疗之前进行局部加强放疗。
  • 接受任何其他同时进行的抗癌或研究药物治疗的患者。
  • 患有任何具有临床意义的无关全身性疾病(严重感染或明显的心脏、肺、肝或其他器官功能障碍)的患者。
  • 无法返回进行随访或无法获得评估治疗毒性所需的后续研究的患者。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:A组
高剂量化疗加外周血干细胞移植,然后是 TTRNA-xALT 和 TTRNA-DC。
TTRNA-xALT 3 x 10^7/kg 静脉注射一次。
TTRNA-DCs 1 x 10^7 皮内注射,每 2 周一次,共 3 次总剂量。
实验性的:B组
NMA 补救化疗加外周血干细胞移植,然后进行 TTRNA-xALT 和 TTRNA-DC。
TTRNA-xALT 3 x 10^7/kg 静脉注射一次。
TTRNA-DCs 1 x 10^7 皮内注射,每 2 周一次,共 3 次总剂量。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
12 Month Progression-free Survival (PFS-12)
大体时间:up to 12 months

PFS-12 is the number of participants (%) with PFS at 12 months. PFS is defined as time interval from date of first DC vaccine to date of progression (death is also treated as progression) or censoring, whichever happens first.

The PFS-12 of Historical Benchmark is 33%. The granular PFS of Historical Bechmark is 4,16, 5, 12, 14, 7, 5, 5, 12, 9, 24 and 13 months (Gururangan et al,. Neuro Oncol. 2008, Table 3)

up to 12 months

次要结果测量

结果测量
措施说明
大体时间
Objective Radiographic Response Rate
大体时间:Baseline MRI (prior to Adoptive Cellular Therapy (ACT)) compared to post-ACT MRI (approximately 8 weeks post-baseline MRI)
Objective Response Rate (ORR), defined as the proportion of subjects who show partial or complete response (CR+PR) to therapy, SD (stable disease), and PD (progressive disease) or not assessable, using RECIST criteria based on their best overall response over 8 weeks when comparing pre-ACT vs. post-ACT MRI.
Baseline MRI (prior to Adoptive Cellular Therapy (ACT)) compared to post-ACT MRI (approximately 8 weeks post-baseline MRI)
Change in Cytokine Profile for IFNg
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post ACT therapy for patients in Arm A and Arm B. We will compare baseline (pre-ACT) to post treatment (both TTRNA-xALT and TTRNA-DCs vaccines administered) changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Overall Survival (OS) Rate
大体时间:baseline up to 12 months

12-month OS calculated based on benchmark.

OS-12 is the proportion of participants with OS at 12 months.

baseline up to 12 months
Change in Type 1 Interferon
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in cellular immunity in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 28 (including Day 14) with each patient. OS Univariable Cox Regression with Change in Cellular Immunity was applied. The Hazard Ratio with 95% CI reported.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Type 2 Interferon
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in cellular immunity in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 28 (including Day 14) with each patient. OS Univariable Cox Regression with Change in Cellular Immunity was applied. The Hazard Ratio with 95% CI reported.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Percentage of CD8 Naive T Cells in PBMC
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in lymphocyte phenotype in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline (pre-treatment) to 28 days with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Cytokine Profile for IL10
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Cytokine Profile for IL12p70
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Cytokine Profile for IL2
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Cytokine Profile for IL4
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Cytokine Profile for IL6
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Cytokine Profile for TNFa
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure serum cytokines in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in TLR Activation Status
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in TLR activation status in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to Day 14 and 28 with each patient serving as own control using mixed linear effect model. We quantified pathway activity using GSVA applied to normalized RNA-seq expression data. The enrichment score for each sample was defined as the maximum deviation from zero of this running sum, yielding a dimensionless GSVA score that represents the relative coordinated up- or down-regulation of TLR pathway genes within that sample compared to the background transcriptome. Higher GSVA score represents upregulation and lower GSVA score represents downregulation. There is no clinical relevance threshold.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Percentage of CD8 Memory T Cells in PBMC
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in lymphocyte phenotype in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to 28 days with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Percentage of CD4 Naive T Cells in PBMC
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in lymphocyte phenotype in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to 28 days with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Percentage of CD4 Memory T Cells in PBMC
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in lymphocyte phenotype in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to 28 days with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Percentage of Treg T Cells in PBMC
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in lymphocyte phenotype in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to 28 days with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
Change in Percentage of NK Cells in PBMC
大体时间:baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)
We will measure change in lymphocyte phenotype in peripheral blood pre and post therapy for patients in Arm A and Arm B. We will compare baseline to post treatment changes for each arm. Longitudinal difference baseline to 28 days with each patient serving as own control using mixed linear effect model.
baseline prior to immunotherapy to 28 days post-vaccine #1 (both TTRNA-xALT and TTRNA-DCs vaccines administered)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Duane Mitchell, MD, PhD、University of Florida

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年9月7日

初级完成 (实际的)

2020年3月28日

研究完成 (实际的)

2025年3月28日

研究注册日期

首次提交

2010年7月22日

首先提交符合 QC 标准的

2011年3月29日

首次发布 (估计的)

2011年3月30日

研究记录更新

最后更新发布 (实际的)

2026年8月13日

上次提交的符合 QC 标准的更新

2026年7月23日

最后验证

2025年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • IRB201500502
  • W81XWH-10-1-0089 (其他赠款/资助编号:Department of Defense)
  • CDMRP-PRO93877 (其他标识符:Department of Defense)
  • OCR13166 (其他标识符:University of Florida)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅